End-to-end DNA sequencing solution with Exatype and Roche

Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 panel.

/images/roche/icon-hex-red.svg Hyrax Biosciences and Roche have partnered to enable integrated sample prep to reporting workflows for sequencing-based testing and research.

Pairing Hyrax Biosciences' Exatype platform with Roche's KAPA HyperCap workflow provides an integrated, end-to-end solution from sample prep through to data analysis, interpretation and reporting.

Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) thereby making sequencing for SARS-CoV-2 genomic surveillance faster, cheaper and more accurate.


Viral RNA in host RNA background


Library Prep with KAPA RNA HyperPrep Kit


Target Enrichment with KAPA HyperCap SARS-CoV-2 panel


Final library enriched with viral targets


Next Gen Sequencing


Analysis and reporting using the Exatype platform


Try our Exatype SARS-CoV-2 Analysis Solution for Free

Sign up at hpr.exatype.com and run your first samples for free!

Experience the full workflow - a demo dataset is included in the welcome email upon signup, but you are welcome to use your own Roche KAPA HyperCap SARS-CoV-2 data instead.


Benefits of Roche Sequencing Analysis with Exatype

Exatype has been tailored for the analysis of sequence data generated using Roche’s KAPA HyperCap SARS-CoV-2 panel:


Automated primer deduplication

Report variant prevalences with confidence


Customisable prevalence setting for variant detection

Harness the power of Exatype’s algorithms in detecting low abundance variants e.g. surveillance studies and detection of dual-infection


Easy to use

Intuitive drag-and-drop interface means minimal end-user input needed to analyse data



Scale up with ease using Hyrax Biosciences’ streamlined and secure, cloud-based IT infrastructure


High quality results

Confidently detect and report variants with the Exatype platform


Minimise time

Report your findings faster by on-cloud parallel processing using the intuitive interface of the Exatype platform


Proven expertise

Hyrax Biosciences’ proven expertise in viral sequence and reporting offers reliable SARS-CoV-2 surveillance



APIs enable direct integration with sequencers and/or LIMS (contact us for more information)

Get in touch


Further information


Read more about the Hyrax-Roche co-promotion partnership.

download Download PDF


Learn more about streamlining your SARS-CoV-2 sequencing with the Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) and the Exatype platform.

download Download PDF

The Exatype Platform: An end-to-end Bioinformatics Software Platform

Our modular platform can analyse and interpret sequence data from an ever-expanding range of applications, including:


Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.


Multi-target diagnostics, e.g. infectious disease panels.


Tumour profiling and drug-susceptibility testing in cancer.


Low abundance variant detection e.g. detecting mixed infections or the detection of biomarkers in liquid biopsies.

Your Sequence data.

One Solution.

Discover our sequence-analysis solutions Email sending